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Summary Estimation of tumour proliferation may allow the design of individualised radiotherapy schedules
to optimise response. This prospective study correlates the tumour proliferation rate of cervical carcinoma with
response to conventional radiotherapy. The potential tumour cell doubling rate (Tpot) was estimated following
flash labelling of the tumours in vivo using the DNA precursor, bromodeoxyuridine (BrdUrd); samples were
analysed by flow cytometry. Tumour ploidy, DNA index and mitotic count were also assessed as was
histological grade and type. Multiple biopsies from each tumour were obtained from 121 women. The median
Tpot was 4.0 days, median S-phase duration 12.8 h and median adjusted labelling index 9.8%. Higher BrdUrd
labelling was seen in patients who developed pelvic tumour recurrence following radiotherapy. This was the
only biological/histological parameter with univariate and multivariate significance in relation to locoregional
recurrence (P =0.006 and P =0.034 respectively). This study represents the first assessment ofTpot in relation to
long-term response of cervical tumours treated by radiotherapy treatment. The association of high BrdUrd
labelling and poor pelvic disease-free survival indicates the need for further research into the potential of
radiotherapy schedule alteration to reflect tumour proliferation. The predictive value may be enhanced by
combination with other biological parameters.
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Local recurrence can be a significant problem following
radiotherapy for carcinoma of the cervix. This is particularly
true of more advanced stage tumours. Local recurrence is
seen in only 10% of stage lb patients, but in stage IIIb
disease, pelvic recurrence rate is greater than 40% (Davidson
et al., 1989). Both clinical and laboratory data suggest
repopulation during treatment may be an important factor
leading to failure to achieve local control of the tumour
(Trott and Kummermehr, 1985). In order to reduce
repopulation during treatment, radiotherapy can be given
over a shorter time period, often two or three times a day
using a fraction size of less than 2 Gy. It is unclear whether
all patients would benefit from accelerated radiotherapy
schedules. Initial results from a randomised study of
radiotherapy schedule alteration in head and neck cancer
(Saunders et al., 1991) suggest that local control is improved
in patients receiving accelerated hyperfractionated radio-
therapy in rapidly proliferating tumours only (Begg et al.,
1992). Measurement of tumour proliferation rate may,
therefore, help to select patients most likely to benefit from
new or accelerated schedules for radiotherapy.
There is inconclusive evidence regarding the relationship
between measured tumour proliferation parameters and
prognosis in cervical carcinoma (Dixon et al., 1977; Strang
et al., 1987a,b; Naus and Zimmerman, 1991; Cole et al., 1992;
Zanetta et al., 1992; Tsang et al., 1995). The techniques used
in the measurement of proliferation in these studies included
the assessment of growth fraction using Ki67 immunocyto-
chemistry, the flow cytometric estimation of S-phase fraction
and the tritiated thymidine labelling method. Only one study
used in vivo bromodeoxyuridine labelling (Tsang et al., 1995).
By the separation of the time of tumour labelling and
sampling this technique allows the estimation of labelling
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index and S-phase duration and hence the tumour potential
doubling time (Tpot) (Begg et al., 1985, 1988; Wilson et al.,
1988). It also has the advantage of providing an in vivo
assessment of proliferation.
This paper reports the results from the assessment of
cervical carcinoma proliferation rate through the labelling of
tumours in vivo using bromodeoxyuridine (BrdUrd). Schedule
alteration was not feasible in the context of this study; all
patients received standard radiotherapy schedules extending
over approximately 5 weeks. This cohort of patients has now
achieved a median follow-up of 34 months.
Materials and methods
Selection ofpatients
Over the 2 year study period all patients with cervical
carcinoma scheduled to receive radiotherapy at the Beatson
Oncology Centre, Glasgow, were requested to give written
consent for the administration of BrdUrd. BrdUrd 200 mg
(obtained from the Department of Pharmacy at the
University of Strathclyde) was dissolved in 100 ml of 0.9%
saline and was administered intravenously over 15 min. The
infusion was given 6-8 h before the predicted time of
tumour sampling.
Tissue collection
Multiple tumour samples were collected by obtaining
additional punch biopsies at the time of the staging
procedure, choosing macroscopically viable areas of the
tumour. The time difference between labelling and sampling
was recorded. The biopsies were fixed in 70% alcohol for a
minimum of 24 h.
Sample analysis
Tissue processing and flow cytometric analysis to determine
cell kinetic parameters were performed as describedProliferation rate of cervical tumours
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previously (Bolger et al., 1993). In brief, a nuclear suspension
was produced by pepsin disaggregation of a 50 mg portion of
tumour. The incorporated BrdUrd was revealed through the
partial denaturation of the DNA using hydrochloric acid.
The BrdUrd was detected using a mouse anti-BrdUrd
monoclonal antibody (Dako Ltd., High Wycombe, UK),
and a FITC-conjugated goat anti-mouse antibody (Sigma
Chemicals Ltd., Poole, UK). The DNA was fluorescently
stained using propidium iodide. The samples were analysed
on a Coulter Epics Profile II flow cytometer. Using the flow
cytometer software a DNA frequency histogram, a BrdUrd
frequency histogram and a DNA/BrdUrd cytogram were
constructed.
Calculation of bromodeoxyuridine labelling index
The crude BrdUrd labelling index (crude LI), representing
the fraction of the entire cell population labelled with
BrdUrd, was determined from the BrdUrd frequency
histogram. An adjusted BrdUrd labelling index (adjusted
LI) was estimated from the BrdUrd/DNA cytogram. This
allowed an estimation of the labelling associated with a
specific tumour ploidy population, including compensating
for those cells which have divided since labelling (Begg et
al., 1985).
Calculation of S-phase (Ti) duration
The derivation ofT, assumes that at the time of labelling the
average DNA content of labelled cells lies midway between
the G, and the G2 peaks. It also assumes that the progression
of cells through S-phase is constant. The average cell
progression rate through S-phase can be calculated provided
the mean DNA content of labelled undivided cells and the
time interval between labelling and biopsy is known. All
flash-labelled S-phase cells are expected to reach G2 by a time
equal to T., thus from the progression rate a value for T, can
be derived.
No calculation of T, or adjusted LI could be performed
for aneuploid tumours if there was gross overlap of the S-
phase labelled cells.
Calculated cell kinetic parameters
The potential doubling time was derived from the equation:
adjusted LI
L is a correction factor for the non-linear distribution ofcells
through the cell cycle (Steel, 1977). We have used a constant
value of 0.8 in our calculations.
Radiotherapy schedules
Early lesions (stage I and II<5 cm) received two intracavity
insertions using the selectron after loading machine (16
patients). The average A point dose was 36 Gy (from both
insertions) at a dose rate of 1.8 Gy h-'. This was followed
by 3 weeks' (14 fractions) treatment with 4MeV X-rays to
parallel opposed diamond-shaped fields with the selectron-
treated area covered with a compensation wedge. The total
summated pelvic side wall dose was 42.3 Gy with an A
point dose of 61 Gy±5%. More advanced lesions (bulky
Ilb, III and IVa) were treated over 4 weeks with 4 MeV X-
rays to the true pelvis using a four-field technique to a dose
of 43 Gy in 20 fractions. This was followed by a selectron
insertion of 26 Gy at 1.8 Gy h-'.
Histology
A single histopathological review was performed (RA
Burnett) to define histological type, grade and mitotic rate.
Results
Tumour cell kinetics
Tumour samples were obtained from a total of 121 patients
before commencing radiotherapy. The median age was 61
years, the interquartile range was 47 to 70 years old. The
relative distribution depending on clinical stage was 10.8%,
42.1%, 38.0% and 9.1% for stages I to IV respectively. The
mean tumour diameter was 4.8 cm, interquartile range 3-
6 cm. A mean of 2.8 biopsies were analysed from each
tumour, range 1 -6. The results obtained from the most
proliferative biopsy (shortest Tpot) for each patient were
selected for comparison with clinical parameters presented
within this paper. In all cases the crude BrdUrd LI could be
calculated; in 14/121 cases no calculation of T, or adjusted LI
could be achieved owing to overlapping aneuploid and
diploid populations. The median and interquartile range for
these parameters are shown in Table I.
No differences in proliferation parameters were seen in
relation to clinical stage and tumour size. The median
adjusted LI for stages I to IV was 10.8, 9.7, 9.4 and 16%
respectively (Spearman rank correlation, P=0.21). The
median adjusted LI for tumours <4 cm and 4 cm or greater
was 10.1 and 9.6% respectively (Mann-Whitney, P=0.78).
Similar non-significant differences were seen for Ts and Tpot
measurements.
Radiotherapy response
The median duration of follow-up for surviving patients (58/
121) is 34.6 months, interquartile range 31.5-39.3 months,
minimum follow-up of 23 months. Of the 63 patients who
have died, 19 had pelvic tumour alone, 23 had pelvic and
metastatic tumour, eight had metastatic tumour alone, nine
did not die as a direct result of their tumour and in four cases
the state of disease at death was not recorded. Survival
curves, irrespective of cause of death, were calculated for
patients with above and below median values for each of the
proliferation parameters measured. Patients with above
median labelling have a significantly poorer survival (log-
rank statistics, for crude BrdUrd LI and adjusted BrdUrd LI,
P=0.012 and P=0.048 respectively). Non-significant differ-
ences were seen for Ts and Tpot (P=0.13 and P=0.06
respectively).
To address the question of the relationship between
tumour proliferation and radiotherapy response, the patients
were divided according to pelvic disease-free survival (PDFS).
There was insufficient information to categorise those
patients who had died from non-cancer-related deaths or
metastatic disease owing to the typically short survival
duration (median 16 months). Those patients with uneval-
uated disease at death were also excluded from the analysis.
Therefore, there were 56 patients with PDFS. There was
recurrent local disease in 44 women, two of whom are alive
with pelvic disease. In 90 of these 100 patients calculation of
T, was achieved allowing estimation of the Tpo, Univariate
logistic regression analysis was performed in relation to
PDFS. Analysis of clinical and histological features in
addition to proliferation parameters was undertaken (see
Table II). Increased S-phase duration and elevated BrdUrd
labelling seen in radiotherapy-resistant tumours will have
opposing effects on the calculation of Tp.t. The dominant
factor, however, is the labelling index with a shorter (non-
significant) median Tpot for radiotherapy-resistant tumours
Table I Summary statistics for proliferation parameters
Median Interquartile range
S-phase duration 12.8 h 11.1 to 14.9
Adjusted BrdUrd LI 9.8% 6.7 to 14.5
Potential doubling time 4.0 days 3.1 to 6.3
Crude BrdUrd LI 8.7% 5.7 to 12.4compared with sensitive tumours (3.8 and 4.7 days
respectively). Subgroup analysis depending on the radio-
therapy techniques was not feasible owing to the small
number of patients (16) who received selectron insertion
followed by external beam radiotherapy. However, no
difference in median proliferation parameters for these two
groups was observed.
Stepwise multivariate logistic regression analysis was
performed on the parameters listed in Table II. The model
selected defined only tumour size and adjusted BrdUrd LI as
having independent prognostic significance with regard to
pelvic disease-free survival following radiotherapy (Table III).
All other parameters had P-value>0.17 and were therefore
rejected.
Actuarial pelvic disease-free survival was compared for
above/below median adjusted BrdUrd LI (Figure 1). This
provides consistent evidence that patients with elevated
(above median) labelling have significantly greater chance of
developing a local recurrence (log-rank, P=0.002).
Table II Univariate logistic regression analysis of pathological/
clinical parameters depending on pelvic disease-free survival
P-value Odds ratio 95% CI
Crude BrdUrd LI 0.015 1.12 1.02-1.22
S-phase duration 0.018 1.21 1.03-1.42
Adjusted BrdUrd-LI 0.006 1.12 1.03-1.21
Tpot 0.37 0.93 0.8- 1.09
Histological type 0.46 1.61 0.45-5.6
Grade 0.39 1.5 0.59-3.8
Mitosis 0.75 0.89 0.44- 1.78
DNA ploidy 0.45 0.71 0.3-1.71
DNA index 0.65 1.3 0.45-3.52
Clinical stage <0.001 2.81 1.56-5.1
Tumour size <0.001 1.68 1.31 -2.15
In the analysis of histological type, 11/121 were defined as
adenocarcinoma. Tumours were divided into three groups according
to the mitotic count per high-powered field (< 1, 1 -5, >5) tumour
ploidy was defined as diploid or aneuploid.
Table III Parameters
significance following
shown to have independent prognostic
stepwise multivariate logistic regression
analysis
P-value Odds ratio 95% CI
Adjusted BrdUrd LI 0.034 1.1 1.01-1.2
Tumour size <0.001 1.7 1.26-2.28
1.0I
0.75
0.5
0.25
I-,
BrdUrd labelling index
Below median adjusted
BrdUrd labelling index
10 20 30 40
Time (months)
Figure 1 Pelvic disease-free survival of patients split according to
adjusted BrdUrd labelling index. The analysis includes 90 women
for whom pelvic disease-free survival could be assessed and a
measurement of adjusted BrdUrd LI could be made.
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Discussion
Radiotherapy is a local treatment and the most valid
assessment is locoregional control. The determination of
pelvic disease-free survival, therefore, allows the most
discriminating assessment of the relationship between
tumour cell kinetics and radiotherapy response. This analysis
based on a median survival of 34 months should provide an
accurate prediction of local recurrence rate; in 78% of
women destined to develop pelvic recurrence a diagnosis will
be made within 24 months of treatment (Van Nagell et al.,
1979).
This study indicates that the principal difference in tumour
proliferation parameters where local control was not
achieved, is an elevated proliferating fraction (as indicated
by the increase in BrdUrd labelling index). This is a
consistent finding in uni- and multivariate analysis. These
findings are as predicted by tumour clonogenic repopulation
studies. Interestingly, these results also indicate that T, is
longer in radiotherapy-resistant tumours. There is little
published data on the evaluation of Ts and treatment
response; however, no previous study has defined this
difference. The absolute difference between the median
values of Ts for radiotherapy-sensitive and resistant tumours
is small and the biological significance is uncertain.
Prolongation of T, may result from the fact that a larger
proportion of the cell population is recruited into the cell
cycle with a resultant lengthening of cell cycle time. One
implication of this finding, however, is that the estimation of
Tpot is less predictive of local tumour control because the
lengthening of T, has an opposite effect to the elevation of
BrdUrd LI in the calculation of Tpot. If labelling index alone
is confirmed to provide greatest prognostic information, the
clinical application of these measurements would be
facilitated because it is the simplest parameter to measure
and does not require a labelling/biopsy delay.
A recently published study relating Tpot to radiotherapy
response in cervical carcinoma reports similar findings. The
inability of this study to determine statistically significant
differences may relate to the inadequate follow-up duration
(minimum 7 and mean 16 months) and the small numbers
included in the study (46) (Tsang et al., 1995). This analysis
defines BrdUrd labelling index as the most predictive
parameter, in keeping with our results.
In common with other studies, there is no convincing
evidence that histological type, grade, mitotic index, DNA
ploidy or DNA index are of any predictive value. Analysis of
other histological and clinical features was undertaken to
exclude any association of cell kinetics with these parameters.
The definition ofBrdUrd LI, in a multivariate analysis, as the
second best predictor of local tumour recurrence indicates the
significant role this parameter plays in relation to local
recurrence. It is noteworthy that tumour size has a greater
predictive value than stage. This illustrates the limitations of
the current staging system and clearly demonstrates the value
of the proposed incorporation of tumour size in the FIGO
staging of lb disease (Creasman, 1995). The need to record
tumour size in other stages remains unaddressed.
The radiotherapy schedules used in this centre are
relatively short compared with the conventional schedule
used for head and neck tumours as reported in the EORTC
cooperative trial (Begg et al., 1992). The duration lies at the
point, defined by Begg (1994), below which rapidly growing
tumours are unlikely to gain advantage from further
acceleration. The findings of this study question this
proposed level and, more significantly, indicate that
protraction of treatment schedules beyond 5 weeks may
provide inadequate treatment for tumours with a high
labelling index.
In conclusion, these results indicate that measurement of
pretreatment tumour cell kinetics may predict failure to
achieve local tumour control. The BrdUrd labelling index has
the greatest predictive value of all parameters measured. This
data identifies the need to examine current radiotherapy
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treatment schedules and indicates the potential for further
studies of cell kinetics in association with schedule
manipulations in this tumour group. Clearly, the damage to
normal tissue within the radiated field will limit the possible
extent of accelerated fractionation. Other factors, such as
intrinsic tumour radiosensitivity (Davidson et al., 1990) and
apoptosis rate (Levine et al., 1994), have been shown to be
predictive of radiotherapy response. In combination with
these parameters, individualisation of treatment may become
feasible to optimise treatment response.
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